imfinzi® (durvalumab) plus chemotherapy approved in the us as the first immunotherapy regimen...
Published 1 year ago • 393 plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
1:18
imfinzi® (durvalumab) plus chemotherapy approved in the us as the first immunotherapy regimen...
-
52:55
immunotherapy nightmare - imfinzi/durvalumab experience - lung cancer
-
7:44
durvalumab (imfinzi) fda approved for stage iii nsclc: standard of care? (bmic-024)
-
8:28
imfinzi uses: guide to understanding the many benefits of this breakthrough immunotherapy
-
0:42
astrazeneca’s immunotherapy imjudo (tremelimumab) wins fda approval for liver cancer
-
1:37
results for durvalumab in the second-line treatment of nsclc
-
8:16
case based panel discussion - stage 3 nsclc best schedule - durvalumab/imfinzi in varying patients
-
3:31
fda d.i.s.c.o. burst edition: fda approval of imfinzi (durvalumab) for adult patients with locall...
-
2:10
poseidon: 4 year follow up of durvalumab and tremelimumab in nsclc
-
2:25
imfinzi (durvalumab) plus bevacizumab met endpoints in emerald-1 phase iii results in liver cancer
-
3:01
fda d.i.s.c.o. burst edition: fda approval of imjudo (tremelimumab) in combination with imfinzi (...
-
1:09
how immunotherapy is changing cancer treatments
-
24:19
chemotherapy vs immunotherapy: what's the difference
-
1:06:23
immunotherapy in lung cancer: rationale, evidence, and implications for the multidisciplinary team
-
7:45
onctalk 2021 - pdl1 and imfinzi/durvalumab
-
0:43
double immunotherapy with durvalumab and tremelimumab versus quadruple therapy in nsclc
-
21:02
immunotherapy innovations in 2022
-
2:18
imfinzi (durvalumab)- non-small cell lung cancer (nsclc)
-
2:34
dr. langer on practice-changing pacific data in stage iii nsclc